Literature DB >> 27551109

Chemotherapy for Triple-Negative Breast Cancer: Is More Better?

Erica L Mayer1, Harold J Burstein2.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 27551109     DOI： 10.1200/JCO.2016.68.4068

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  15 in total

1.  Transport-driven engineering of liposomes for delivery of α-particle radiotherapy to solid tumors: effect on inhibition of tumor progression and onset delay of spontaneous metastases.

Authors:  Rajiv Nair; Omkar Bhatavdekar; Aprameya Prasad; Alaina Howe; Dominick Salerno; Michelle Sempkowski; Anders Josefsson; Jesus Pacheco-Torres; Zaver M Bhujwalla; Kathleen L Gabrielson; George Sgouros; Stavroula Sofou
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-06-12       Impact factor: 9.236

2.  Targeted Heating of Mitochondria Greatly Augments Nanoparticle-Mediated Cancer Chemotherapy.

Authors:  Jiangsheng Xu; James G Shamul; Hai Wang; John Lin; Pranay Agarwal; Mingrui Sun; Xiongbin Lu; Katherine H R Tkaczuk; Xiaoming He
Journal:  Adv Healthc Mater       Date:  2020-06-17       Impact factor: 9.933

3.  MiR-25-3p promotes the proliferation of triple negative breast cancer by targeting BTG2.

Authors:  Hua Chen; Hong Pan; Yi Qian; Wenbin Zhou; Xiaoan Liu
Journal:  Mol Cancer       Date:  2018-01-08       Impact factor: 27.401

Review 4.  Metronomic chemotherapy for non-metastatic triple negative breast cancer: Selection is the key.

Authors:  Connie Rabanal; Rossana Ruiz; Silvia Neciosup; Henry Gomez
Journal:  World J Clin Oncol       Date:  2017-12-10

5.  Precise targeting of POLR2A as a therapeutic strategy for human triple negative breast cancer.

Authors:  Jiangsheng Xu; Yunhua Liu; Yujing Li; Hai Wang; Samantha Stewart; Kevin Van der Jeught; Pranay Agarwal; Yuntian Zhang; Sheng Liu; Gang Zhao; Jun Wan; Xiongbin Lu; Xiaoming He
Journal:  Nat Nanotechnol       Date:  2019-02-25       Impact factor: 39.213

6.  FKBP12 is a predictive biomarker for efficacy of anthracycline-based chemotherapy in breast cancer.

Authors:  Mingyou Xing; Jun Wang; Qin Yang; Yu Wang; Jiansha Li; Jing Xiong; Sheng Zhou
Journal:  Cancer Chemother Pharmacol       Date:  2019-08-19       Impact factor: 3.333

7.  Adjuvant Capecitabine With Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): An Open-Label, Randomized, Multicenter, Phase III Trial.

Authors:  Junjie Li; Keda Yu; Da Pang; Changqin Wang; Jun Jiang; Suisheng Yang; Yunjiang Liu; Peifen Fu; Yuan Sheng; Guojun Zhang; Yali Cao; Qi He; Shude Cui; Xijing Wang; Guosheng Ren; Xinzheng Li; Shiyou Yu; Pengxi Liu; Xiang Qu; Jinhai Tang; Ouchen Wang; Zhimin Fan; Guoqin Jiang; Jin Zhang; Jiandong Wang; Hongwei Zhang; Shui Wang; Jianguo Zhang; Feng Jin; Nanyan Rao; Binlin Ma; Pingqing He; Binghe Xu; Zhigang Zhuang; Jianfeng Wang; Qiang Sun; Xiaofeng Guo; Miao Mo; Zhimin Shao
Journal:  J Clin Oncol       Date:  2020-04-10       Impact factor: 44.544

8.  Optimizing cisplatin delivery to triple-negative breast cancer through novel EGFR aptamer-conjugated polymeric nanovectors.

Authors:  Mauro Comes Franchini; Laura Cerchia; Lisa Agnello; Silvia Tortorella; Annachiara d'Argenio; Clarissa Carbone; Simona Camorani; Erica Locatelli; Luigi Auletta; Domenico Sorrentino; Monica Fedele; Antonella Zannetti
Journal:  J Exp Clin Cancer Res       Date:  2021-07-22

9.  Albumin Nanoparticle of Paclitaxel (Abraxane) Decreases while Taxol Increases Breast Cancer Stem Cells in Treatment of Triple Negative Breast Cancer.

Authors:  Hebao Yuan; Hongwei Guo; Xin Luan; Miao He; Feng Li; Joseph Burnett; Nathan Truchan; Duxin Sun
Journal:  Mol Pharm       Date:  2020-06-17       Impact factor: 4.939

10.  Targeting lysyl oxidase (LOX) overcomes chemotherapy resistance in triple negative breast cancer.

Authors:  Ozge Saatci; Aysegul Kaymak; Umar Raza; Pelin G Ersan; Ozge Akbulut; Carolyn E Banister; Vitali Sikirzhytski; Unal Metin Tokat; Gamze Aykut; Suhail A Ansari; Hayriye Tatli Dogan; Mehmet Dogan; Pouria Jandaghi; Aynur Isik; Fatma Gundogdu; Kemal Kosemehmetoglu; Omer Dizdar; Sercan Aksoy; Aytekin Akyol; Aysegul Uner; Phillip J Buckhaults; Yasser Riazalhosseini; Ozgur Sahin
Journal:  Nat Commun       Date:  2020-05-15       Impact factor: 14.919
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.